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Summary 
Triggering of the T cell antigen receptor (TCR) complex activates the serine/threonine kinase 
Raf-1 whose function is necessary for TCR induction of the interleukin 2 gene. Raf-1 has been 
identified as a candidate mitogen-activated  protein (MAP) kinase kinase kinase (MKKK) and 
thus has the potential  to couple the TCR to the activation of the MAP kinases such as ERK2. 
In the present study, the role of Raf-1 in ERK2 regulation of ERK2 in T cells has been explored. 
A constitutively active Raf-1 kinase, v-tar, or a dominant inhibitory Raf-1 mutant were expressed 
transiently from the pEF BOS vector in Jurkat cells and the effects of these Raf-1 mutants on 
a coexpressed ERK2 reporter was assessed. The action of the constitutively active Raf-1 was 
to stimulate  the ERK2 kinase, whereas the dominant negative version of Raf-1 inhibited the 
ERK2 activation induced by triggering of the TCR.  These data indicate a role for Raf-1 in 
the regulation of ERK2 in T  cells. 
T  lymphocyte  activation is controlled by the TCR for for- 
eign antigen. The TCR is a multichain complex com- 
posed of a heterodimer of the idiotypic ot and/3 chains non- 
covalently associated with the invariant % ~, e chains of the 
CD3 antigen and the TCR-~" subunit (1). Triggering of the 
TCR in conjunction with signals generated by accessory  mol- 
ecules such as CD2, CD4, CD8, and CD28 control T cell 
activation by regulating the expression of genes encoding 
cytokines and cytokine receptors (2). 
The TCR is coupled via its cytoplasmic domain to a pro- 
tein tyrosine kinase signaling cascade (3, 4) that couples the 
TCR to two important signal transduction molecules: the 
guanine nucleotide binding proteins  p21ras (5) and an ino- 
sitol lipid-specific phospholipase C, PLCyl (6). PLCyl con- 
trols the metabolism of inositol phospholipids thereby gen- 
erating inositol  polyphosphates  that mobilize intracellular 
calcium and diacylglycerols that stimulate the serine/threo- 
nine kinase, protein kinase C  (PKC) (7, 8). 
Several other serine/threonine kinases are activated by the 
TCR, namely mitogen-activated  protein kinases (MAP ki- 
nases) such as ERK1 and ER_K2 and the kinase encoded by 
the protocogene Raf-1  (9-12).  In fibroblasts and neuronal 
cells, Raf-1 appears to transmit signals important in gene ex- 
pression, cell growth, and differentiation (13, 14). In T cells, 
moreover, it has been demonstrated that Raf-1 activity is neces- 
sary for TCR induction of IL-2 gene transcription and secre- 
tion (15). It is not known how Raf-1 contributes to cytokine 
gene regulation although recent studies of Raf-1 function 
have suggested that Raf-1 is an important component of the 
signaling pathways that stimulate MAP kinases such as ERK1 
and 2 (16, 17). The MAP kinases are activated by a kinase 
cascade involving  a MAP kinase kinase (MKK) that phos- 
phorylates and stimulates the ERK1 and 2 kinases directly 
(18). The activity of the MKK is itself controlled by phos- 
phorylation and hence a MAP kinase kinase kinase (MKKK) 
plays a crucial role in the regulation of ERK1  and 2 (19). 
In some cells Raf-1 has been identified as a MKKK that plays 
a key role in coupling p21ras and hence receptors that stimu- 
late p21ras to the MAP kinases (20, 21). Raf-1 is equally im- 
portant in PKC and G-protein coupled mechanisms for MAP 
kinase activation in certain cell systems (20, 22). The MAP 
kinase ERK2 can phosphorylate and regulate transcriptional 
factors such as cziun and Elk1 (23, 24). Hence if Raf-1 was 
involved in coupling the TCR to ERK2 then the ability of 
ERK2 to translocate to the nucleus where it can directly modu- 
late transcriptional factors could explain the Raf-1 role in TCR 
signal transduction. 
Recently, we demonstrated that TCR triggering results 
in the activation of ERK2 by a p21ras-dependent mechanism 
(25). Raf-1 is one candidate for the MKK that couples p21ras 
and the TCR to the MKK and hence to ERK2. However, 
the role of Raf-1 in TCR stimulation of ERK2 has not yet 
been explored and it should be noted that Raf-1 is not the 
only candidate MKKK since a murine homologue of two 
yeast MKKKs  (termed MEKK)  has been isolated that can 
stimulate the MKK without activating Raf-1 (26). Further- 
more, activation of the ERK2 pathway may not explain the 
stimulatory effect of expression of constitutively Raf-1 on 
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lator of the NFxB family of transcriptional factors, is a sub- 
strate for Raf-1 (27,  28) and this could allow Raf-1 to have 
a role in the control of gene transcription that is independent 
of its ability to regulate MAP kinases.  In this context, acti- 
vated Raf-1 mutants fail to stimulate the MAP kinase pathway 
in every cell system (29, 30), which supports the possibility 
that Raf-1 may have cellular functions in addition to its poten- 
tial role as a MKK. 
The object of the present study was to examine the role 
of Raf-1 in MAP kinase regulation in T cells. ERK2 is the 
predominant TCR stimulated MAP kinase (10, 25) and the 
data demonstrate that expression  of a constitutively active 
Raf-1 in T  cells stimulates ERK2 whereas expression of a 
dominant negative Raf-1 suppresses TCR induction of  ERK2. 
These studies implicate Raf-1 as an essential component of 
the MAP kinase cascade in T  cells. 
iodacetamide, 1 mM PMSF, 100 #M Na3VO4).  After 20 min of 
preclearing with insoluble protein A-Sepharose suspension, lysates 
were incubated for 20 min with 2 #g of 9E10 antibody, then for 
1 h with 20 #1 of a 50% suspension of protein G-Sepharose beads 
(Sigma Chemical  Co., Poole,  UK). Immunoprecipitates  were washed 
three times with lysis  buffer and once with kinase assay  buffer (30 
mM Tris [pH 8], 2 mM MgC12, 2 mM MnC12). In vitro kinase 
assays were carried out for 30 rain at room temperature in 20 #1 
of kinase assay buffer supplemented with 10 /xM ATP, 5 /zCi 
3'-[32p]ATP, and 10/zg myelin basic protein (MBP) as a substrate. 
The kinase reaction was stopped with 20 #1 of 2 x  SDS sample 
buffer and samples were run in 15% SDS-PAGE minigels. Quanti- 
tation of 32p incorporated into the MBP protein band was done 
by B-radiation  scanning of  dried gels using a scanner (AMBIS, Inc., 
San Diego, CA). The assay  is linear  with regard to time and amount 
of kinase activity. All MBP kinase activity in  ERK2-tag  im- 
munoprecipitates was normalized to the relative amount of ERK2- 
tag protein expressed in different cell populations as assessed by 
Western blotting analysis (25). 
Materials and Methods 
Plasmids and Antibodies.  A tagged ERK2 reporter construct was 
generated as described (16) using a COOH-terminal epitope tag 
from c-myc that is recognized by the monoclonal antibody 9E10. 
The ERK2-tag encoding DNA was subcloned  into the mammalian 
expression vector pEF-Bos (31). The pEF-Bos expression  vector was 
also used to direct expression of v-tar, a gag-Raf fusion protein 
with constitutively high kinase activity (32) and a COOH ter- 
minus truncated Raf-1 (amino acids 1-257) that has a dominant 
negative phenotype (20, 21, 33). The antibodies  UCHT1 and 9E10, 
reactive with the 6 chain of the human TCR/CD3 antigen com- 
plex and the c-myc epitope tag, respectively,  were purified from hy- 
bridoma supernatants by affinity chromatography with protein 
A-Sepharose. Rabbit antisera that recognizes  ERK1 and ERK2 (an- 
tisera 124) (34) or Raf-1 were used to visualize endogenous ERK2 
and Raf-1 by Western blotting (35). 
Cell and Transfections.  Jurkat cells were maintained in RPMI 
1640 supplemented with 10% heat inactivated FCS. Growth was 
at 37~  in a humidified 5% CO2/95%  air incubator. Cells were 
transfected via electroporation (Gene Pulser; Bio-Rad Laboratories, 
UK),  according to the manufacturer's instructions. Briefly, cells 
were incubated with the indicated concentration of plasmid DNA 
and then pulsed (1-1.5  x  107 in 0.5 ml medium) at 960 mF and 
310 V. Transfected cultures were maintained in culture for 24 h 
and afterwards were harvested for subsequent procedures. 
Western Blotting.  Acetone-precipitated  protein from cell lysates 
corresponding to 106 cells was resolved in SDS-PAGE gels. Blots 
were probed as previously  described  with 9El0 antibody to visualize 
the ERK2-tag protein (16). To detect endogenous ERK-2 or Raf-1, 
blots were probed with specific antisera as previously described 
(34, 35). To  detect immunocomplexes the Western blots  were 
probed with either horseradish peroxidase (HRP)-coupled rabbit 
anti-mouse  or HRP-coupled goat anti-rabbit  followed by elec- 
trochemiluminescence  (ECL; Amersham International, Little Chal- 
fort, UK). 
Analysis of  ERK-tag Kinase Activity.  Jurkat cells were transfected 
with the indicated concentration of pEF-BOS ERK2-tag. After 
24-h 1-1.5  x  10  6 cells/assay  point were activated as indicated at 
37~  in 1 ml of RPMI 1640. Thereafter immunoprecipitates of 
ERK2-tag were prepared using the 9E10 monoclonal antibody. 
Briefly, cells were lysed in 0.5 ml lysis buffer (1% Triton X 100, 
50 mM Hepes [pH 7.4], 150 mM NaC1, 20 mM NaF, 20 mM 
Results 
Activation of  ERK2 and Hyloerlohosphorylation  of  Raf l in TCR 
and Phorbol Ester-treated T Cells.  The activation of endoge- 
nous ERK2 can be monitored by Western blot analysis with 
an ERK2-specific antiserum because the activation of ERK2 
requires its phosphorylation on threonine and tyrosine residues 
and the phosphorylated "active" ERK2 has a reduced mo- 
bility on SDS-PAGE gels compared with nonphosphorylated, 
"inactive" ERK2 (34).  The experiment depicted in Fig.  1 
A shows the reduced mobility ofERK2 inJurkat cells treated 
with the PKC activator Pdbu and the CD3 antibody UCHT1 
compared with control unstimulated cells. Stimulation with 
UCHT1 induced a transient mobility shift in the band cor- 
responding to ERK2 that was readily detectable  within 1 
min of exposure to UCHT1,  maximal at 10min but had 
returned to basal by 30 min. Pdbu also induced a rapid shift 
in ERK2 mobility that was maintained even after 30 rain. 
Previous studies have shown that Raf-1 is activated rapidly 
in TCR and phorbol ester-stimulated T cells (12). It is also 
well documented that Raf-1 is hyperphosphorylated in re- 
sponse to T  cell activation (11) and this hyperphosphoryla- 
tion of Raf-1 correlates  with activation of the enzyme, al- 
though it is apparently not directly involved in mediating 
the increase in Raf-1 enzymatic activity (29).  Hyperphos- 
phorylated Raf-1 has reduced mobility on SDS-PAGE gels 
hence to determine whether Raf-1 is hyperphosphorylated 
in Jurkat cells, a Western blot of cell lysates prepared  from 
cells treated with UCHT1 or Pdbu was probed with a Raf-1 
antisera.  The data in Fig. 1 B show that both UCHT1 and 
Pdbu induce a shift in Raf-1 mobility. The kinetics of the 
Raf-1 mobility shift are delayed in comparison with the ERK2 
response. In both UCHT1- and Pdbu-treated cells the Raf-1 
mobility shift was only discernable at the 10-min time-point 
and maintained at 30 min. 
Stimulation of  ERK2 by ExFression of v-raf  The Raf-1 hyper- 
phosphorylation in TCR-activated Jurkat cells indicates that 
Raf-1 is involved in a signal transduction pathway regulated 
by the TCR. However, to determine whether Raf-1 is in- 
402  ERK2  Regulation  in T Lymphocytes epitope tagged ERK2 is transiently expressed in Jurkat cells. 
The epitope tag on ERK2 is a c-myc polypeptide that is rec- 
ognized by the monoclonal antibody 9E10,  thus allowing 
both Western blot quantitation and immunoprecipitation of 
ERK2-tag (16). The kinase activity of the transfected ERK2- 
tag  can be  quantitated  by kinase  assays on  the  9E10  im- 
munoprecipitates using MBP as a substrate. The advantage 
of this assay is that it can be readily applied to explore the 
regulatory effects of  cotransfected, constitutively active or dom- 
inant negative Raf-1 mutants. 
The consequences of the expression of the constitutively 
active v-Raf on ERK2 tag activity is shown in Fig.  2. MBP 
kinase assays were carried out on ERK2-tag immunoprecipi- 
tares isolated from v-Raf or control transfected cells. ERK2 
isolated from unstimulated Jurkat cells has minimal activity 
that is rapidly stimulated when cells are treated with Pdbu 
or UCHT1 (Fig. 2). There was a marked increase in the basal- 
specific ERK2-tag kinase activity isolated from v-Raf-trans- 
fected cells compared with control cells (Fig. 2). The expression 
of v-Raf induced an increase in ERK2-tag kinase activity in 
Jurkat cells that was comparable to the ERK2 activity ob- 
served in T  cells activated via the TCR but somewhat less 
than the ERK2 activity present in phorbol ester treated T 
cells. The stimulatory effect of v-raf on ERK2 activation could 
be further enhanced by exposure of cells to PDBu or UCHT1 
(Fig.  2). 
Figure  1.  Triggering of the TCR hyperphosphorylates  ERK2 and 
RAF-1. Lysa[es  from  Jurkat cells  either  unstimulated  (labeled  C) or stimu- 
lated for the indicated  time points with 100 ng/ml PDBu, 10 mg/ml of 
the TCR agonist UCHT1 were resolved  by SDS PAGE and subjected  to 
Western blot analysis with 124 antiserum or Raf-1 antisera to visualize 
ERK2 (.4) and Raf-1 (B). 
volved in the signaling mechanism used by the TCR to stimu- 
late ERK2 it is necessary to examine the requirement for Raf-1 
in TCR stimulation ofERK2. Raf-1 is a 72-kD serine/threo- 
nine kinase composed of an NH2-terminal regulatory do- 
main and a COOH-terminal catalytic domain. Truncations 
of Raf-1 that remove the NH2-terminal domain generate a 
constitutively active kinase (36). To examine the role of Raf-1 
in ERK2 activation in T cells, the effect of a v-Raf, on ERK2 
kinase activity was examined. The v-rafconstruct used is a 
gag Raf fusion protein with constitutively high Raf kinase 
activity, under the control of the pEF BOS expression vector. 
For these studies a sensitive assay for ERK2 kinase expres- 
sion and function, developed previously to explore the role 
of p21  ras in ER.K2 regulation in T  cells (25), was used. An 
-a  2c 
mew  I 
Control  TcR  PDBu 
Stimuli 
v-Raf activates ERK2-tag in Jurkat cells. Jurkat cells were  Figure  2. 
cotransfected  with either 40/~g of pEFempty  vector and 40/~g of pEF- 
ERK2-tag (EFe) or 40/~g of the pEFv-RAF vector and 40/~g of pEF- 
ERK2-tag (EFraf). After 24 h of culture cells were either unstimulated 
(control) or stimulated for 10 min with PDBu (100 ng/ml) or UCHT1 
(10/zg/ml). ERK2 tag was immunoprecipitated  with the 9E10 antibody. 
Kinase assays  with MBP as a substrate  were set up on the immunoprecipi- 
tates, and the phosphorylated  MBP was resolved  by 15% SDS-PAGE  of 
the products of the kinase assay. Data are expressed  as cpm of 32p incor- 
porated into MBP as assessed by ~-scanning of the band corresponding 
to MBP (AMBIS, Inc.). The ERK-2 activation  data obtained  in three ex- 
periments are expressed  as fold induction in MBP phosphorylation. All 
kinase data was normalized to the level of ERK2-tag expressed in the 
different  populations. This was assessed  by Western  blot analysis  of  ERK2- 
tag expression  with the 9E10 antibody. 
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vation in T Cells.  The studies with v-raf suggest that Raf-1 
induces EKK2 activation but to determine whether Raf-1 
is involved in TCR signaling we examined the effect of a 
dominant inhibitory Raf-1  mutant on TCR activation of 
ERK2. A mutant of Raf-1 was generated that was composed 
of only the NH2-terminal regulatory domain (amino acids 
1-256) without the COOH-terminal catalytic domain (33). 
Previous studies have established that the expression of the 
regulatory domain without the kinase domain results in a 
protein that selectively  inhibits endogenous Raf-1 activity 
with a dominant inhibitory effect (15, 21). To determine the 
effect of the inhibition of endogenous Raf-1 on ERK2 acti- 
vation, Jurkat cells were transfected with the COOH-terminal 
truncated Raf-1 and the activity of cotransfected ERK2 tag 
was assessed. The data in Fig.  3 A  show that unlike v-raf, 
expression of the dominant negative Raf-1 did not increase 
the basal levels of ERK2 tag activity but almost completely 
suppressed  the stimulation of ERK2 induced by TCR trig- 
gering or activation of PKC by phorbol esters. This inhibi- 
tion of ERK2 tag activity was not due to inhibition of  ERK2 
tag expression.  In each experiment ERK2 tag expression was 
confirmed and quantitated by Western blot analysis with the 
9E10 antibody (Fig.  3 B). 
Discussion 
The current studies examine the role of Raf-1 in ERK2 
regulation in T lymphocytes. The data demonstrate that ex- 
pression of a constitutively  active Raf-1 kinase in T cells results 
in activation of ERK2 to a level comparable to that induced 
by TCK triggering. In addition the data demonstrate that 
expression  of dominant inhibitory form of Raf-1 prevents 
ERK2 activation induced by the TCR. These results indi- 
cate that Raf-1 plays a critical role in the TCR regulation 
of the MAP kinase cascade. Previous studies have shown that 
Raf-1 plays an crucial role in T  cell  IL-2 production (15). 
The ability of Raf-1 to control the MAP kinase signaling 
pathway could explain the function of Raf-1 in the regula- 
tion of IL-2 gene transcription. This is because MAP kinases 
are important for controlling the activity of the AP-1 family 
of transcriptional factors (37) that are proposed to contribute 
to the regulation of IL-2 gene expression by interacting with 
several dements within the IL-2  promoter (38). 
Although active Raf expression was sufficient to stimulate 
ERK2 it was observed  that signals  generated by the TCR 
and by phorbol esters were additive with v-raffor ERK2 in- 
duction. This phenomenon could reflect that the expression 
of the constitutively active v-rafconstruct was suboptimal. 
Alternatively the data may imply that the TCR and PKC 
can provide a signal not supplied by v-raf for MAP kinase 
activation. It is well established  that MAP kinase activity is 
controlled by a phosphorylation cascade and the ability of 
v-rafto stimulate ERK2 in T cells is consistent with its ability 
to function as a MKKK and hence control the function of 
the MKK that phosphorylates  and regulates ERK2. The TCR 
could contribute to ERK2 regulation by generating additional 
signals that positively regulate the MKK independently of 
Figure 3.  Effect of a dominant negative 
Raf-1 on ERK2-tag  regulation  in Jurkat cells. 
Jurkat cells were cotransfected with either 
20 #g of the pER-ERK2-tag  vector  and 40/zg 
of the pEF empty  vector  (EFe) or 30 #g of the 
pEF-ERK2-tag vector  and 40 #g of the pEF- 
vector expressing the COOH-terminal trun- 
cated Raf-1  (EFDNraf).  After  20 h of  transfec- 
tion cells were either unstimulated  (control) 
or stimulated  for 10 min with Pdbu  (20 ng/ml) 
or UCHT1 (10/zg/ml). (,4) 9E10 IPs were  car- 
tied out on the lysates  and ERK2-tag activity 
was assessed  using  the MBP kinase  assay  as in- 
dicated above. All kinase  data  was normalized 
to the level of ERK2-tag expressed in the 
different  populations  as assessed  by Western  blot 
analysis  of  ERK2-tag  expression  with the 9E10 
antibody. Results  are expressed as fold  induc- 
tion ERK2-tag  activity  as an average  (mean + 
SD) of the data  obtained  in three  experiments. 
(B) Western  blot analysis  with 9E10 of  the myc 
tagged  ERK2-tag  in T cells  expressing  ERK2- 
tag alone or ERK2-tag together with domi- 
nant negative  Raf-1. 
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tribute to ERK2 activation via regulation of cellular phos- 
phatases. In vivo phosphorylation levels always reflect the bal- 
ance of the activities of kinases  and phosphatases and it is 
thus noteworthy that it has been shown that cell phospha- 
tase activity may be rate limiting for Raf-1 regulation of  ERR2 
(29).  Recent studies have identified a dual specificity phos- 
phatase, MKP-1, that dephosphorylates ERK2 in vivo. (39). 
A related dual specificity  phosphatase, PAC-1,  is expressed 
in mitogen activated T cells (40). It is thus possible that the 
TCR normally regulates ERK2 by controlling the activities 
of positive regulators of ERK2 such as Raf-1 and negative 
regulators such as PAC-1. 
The effects of active and dominant negative Raf-1 on T 
cell ERR2 regulation are similar to the effects of active and 
dominant negative p21ras reported previously (25). It has been 
shown that the NH2-terminal regulatory domain of Raf-1 
can interact directly with activated GTP bound p21ras which 
supports the genetic evidence that Raf-1 is an effector mole- 
cule of p21ras (33,  41). Thus the fact that both Raf-1 and 
p21ras function are essential for T cell activation is consistent 
with the model that p21ras couples the TCK to Raf-1 and 
hence to the MAP kinase cascade. The current series of ex- 
periments has not addressed this issue directly. It is also not 
clear whether the physical association between GTP bound 
Ras and Raf-1 is sufficient to activate the kinase or whether 
additional regulatory signals  are required. It has been sug- 
gested that PKC function is necessary for TCK regulation 
of Raf-1 activity (11), In contrast it appears that PKC does 
not play a major role in coupling the TCK to p21ras or ERR2 
(5, 31). Accordingly future studies must investigate the mech- 
anisms of Raf-1 regulation in T cells and determine whether 
Raf-1 is a convergence point for p21ras  and PKC signals. 
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